UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Association between T cell repertoire diversification and both clinical
response as well as toxicity following immune checkpoint blockade in
metastatic cancer patients.
Authors*: David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham,
Lawrence Fong
Abstract #: 3029
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM
Location: Hall A, Poster Board # 351
Post Session: Developmental Therapeutics - Immunotherapy
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3029)
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring
tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy.
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can
enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant
immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients.
Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying
unbiased approaches to studying antigen-specific responses that are modulated in these patients and are
currently developing biomarkers that may be redictive of clinical efficacy.
http://hemonc.ucsf.edu/fonglab/
*UCSF authors in bold
50